Time to progression · people with advanced gastric cancer
Chemotherapy probably leads to lower time to progression compared with best supportive care (moderate certainty).
1 finding from 1 review
Disease-free survival · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
1 finding from 1 review
Induction cisplatin+5-FU+docetaxel vs cisplatin+5-FU: disease-free survival HR 0.72 (95% CI 0.57 to 0.91, P = 0.006; Vermorken 2007). Prior to concurrent chemoradiation: Posner 2007 HR 0.71 (0.56 to 0.90, P = 0.005).…
2 studies
GRADE not reported
Overall survival (total mortality), chemotherapy regimen A vs regimen B · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
1 finding from 1 review
Locoregional control · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone may leads to lower secondary malignant neoplasms compared with same chemotherapy plus radiotherapy (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in death compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in progression/relapse compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Toxicity / adverse effects (harms) of chemotherapy · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
1 finding from 1 review
Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy may leads to higher menstruation recovery or maintenance: compared with chemotherapy alone (low certainty).
2 findings from 1 review
Premature ovarian failure · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy probably leads to lower premature ovarian failure compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Pregnancy · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy showed no clear difference in pregnancy compared with chemotherapy alone (low certainty).
1 finding from 1 review
Ovulation · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy may leads to higher ovulation compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effects: hot flush · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
It is very uncertain whether gnRH agonist plus chemotherapy changes adverse effects: hot flush compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Adverse effects: vaginal dryness · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy showed no clear difference in adverse effects: vaginal dryness compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Overall survival† · people with cutaneous melanoma
Biochemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.94 [0.84, 1.06]
1317 participants
High
Progression‐free survival · people with cutaneous melanoma
Biochemotherapy leads to lower progression‐free survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.9 [0.83, 0.99]
964 participants
High
Tumour response · people with cutaneous melanoma
Biochemotherapy leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 1.36 [1.12, 1.66]
770 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
Biochemotherapy leads to higher toxicity (≥ G3) compared with chemotherapy (high certainty).
1 finding from 1 review
RR 1.35 [1.14, 1.61]
631 participants
High
Overall survival · patients with asymptomatic, incurable, metastatic colorectal cancer
Delayed chemotherapy showed no clear difference in overall survival compared with immediate chemotherapy (low certainty).
1 finding from 1 review
Nausea and vomiting · patients with asymptomatic, incurable, metastatic colorectal cancer
It is very uncertain whether delayed chemotherapy changes toxicity – nausea and vomiting compared with immediate chemotherapy (very low certainty).
1 finding from 1 review